Riskpilot← Back to searchSign inGet full accessHober Biotech AB
ABActiveOrg 5591185854Hårdvallsgatan 14All other professional, scientific and technical activities n.e.c. · NACE 7499Est. 20170 employees
Revenue 2024
SEK 0
EBITDA margin
—
+60% vs 2023
Equity ratio
70.9%
Financial strength
Net profit 2024
SEK -653K
+7% vs 2023
| Revenue | SEK 0 | — |
| EBITDA | SEK -83K | +60% |
| Net profit | SEK -653K | +7% |
| Total assets | SEK 1,7M | -24% |
| Equity | SEK 1,2M | -35% |
| Employees | 0 | — |
Legal name
Hober Biotech AB
Org number
5591185854
Legal form
Aktiebolag
NACE code
7499 · All other professional, scientific and technical activities n.e.c.
Founded
6 juli 2017
Share capital
SEK 50 000
Employees
0
VAT registered
Yes
Audit selected
No
Last report
2024-12-31
Financial year
January – December
Signatory rights
Firman tecknas var för sig av ledamoten suppleanten
Company purpose
Bolaget skall bedriva rådgivning och konsultverksamhet, med särskilt fokus på bioteknik och därtill närliggande områden. Bolaget skall vidare äga och förvalta fast och lös egendom, med särskilt fokus på aktier och andelar i bolag verksamma inom bioteknik och närliggande områden.
Address
Hårdvallsgatan 14
Email
sophia@hoberbiotech.com
Risika for professionals
Risika provides regulated workflow tools for finance, procurement and compliance teams that need monitoring, alerts and an API.
| Item | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|
| Revenue | 0 | 5 030 | 0 | 0 | 0 |
| Staff expenses | — | — | — | — | — |
| EBITDA | −383 | 4 655 | −181 | −206 | −83 |
| Depreciation & amort. | −3 | −526 | −662 | −783 | −511 |
| EBIT | −386 | 4 129 | −843 | −989 | −594 |
| Net financials | — | — | 2 | −3 | −58 |
| Profit before tax | −354 | 2 990 | 5 | −699 | −653 |
| Tax | −0 | −542 | −2 | −0 | −0 |
| Net profit | −354 | 2 448 | 3 | −699 | −653 |
| Item | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|
| Total assets | 127 | 4 656 | 3 542 | 2 258 | 1 713 |
| Equity | 116 | 2 564 | 2 567 | 1 868 | 1 215 |
| Long-term debt | 0 | 0 | 0 | 0 | 0 |
| Short-term debt | 11 | 952 | 682 | 390 | 498 |
| Total debt | 11 | 952 | 682 | 390 | 498 |
EBITDA margin
-8300000.0%
This company
15.8%
Market median
-52531746% vs market
20202024
Equity ratio
70.9%
This company
38.2%
Market median
+86% vs market
20202024
Return on equity
-53.7%
This company
18.4%
Market median
-392% vs market
20202024
Net profit margin
-65300000.0%
This company
8.1%
Market median
-806172940% vs market
20202024
Asset turnover
0.00×
This company
1.12×
Market median
-100% vs market
20202024
Debt / equity
0.41×
This company
0.62×
Market median
+34% vs market
20202024
- Annual report 2024Filed via Bolagsverket / SCB · Period 2024-01-01 – 2024-12-31
- Annual report 2023Filed via Bolagsverket / SCB · Period 2023-01-01 – 2023-12-31
- Annual report 2022Filed via Bolagsverket / SCB · Period 2022-01-01 – 2022-12-31
- Annual report 2021Filed via Bolagsverket / SCB · Period 2021-01-01 – 2021-12-31
- Annual report 2020Filed via Bolagsverket / SCB · Period 2020-01-01 – 2020-12-31
| Name | Role | Member since |
|---|---|---|
| Current (1) | ||
HH | Audit | 2022 |
| Name | Role | Member since |
|---|---|---|
| Current (2) | ||
| Board of Directors | 2022 | |
| Deputy Board Member | 2022 | |
No shareholder data available.
Beneficial ownership (UBO) data access is restricted in Denmark as of September 2025 per the EU 6th AML Directive. Learn more.
Hober Biotech AB 
Accelerated Bio ABBoard members of Hober Biotech AB also hold positions in 0 other companies.
| Person | Role here | Other companies |
|---|---|---|
| Hök Hans Olov Erik Forsberg | Audit | 0 companies |
| Sophia Elisabeth Hober | Board of Directors | 0 companies |
| Dag Magnus Hober | Deputy Board Member | 0 companies |